Truist Securities raises Alkermes stock price target to $55 on positive trial data

Investing.comMonday, November 17, 2025 at 10:09:07 AM
Truist Securities raises Alkermes stock price target to $55 on positive trial data
  • Truist Securities has increased Alkermes' stock price target to $55, driven by encouraging results from recent clinical trials. This adjustment highlights the firm's positive sentiment towards Alkermes' potential growth and market performance.
  • The raised price target is significant for Alkermes as it may enhance investor confidence and attract more interest in the stock, potentially leading to increased trading volume and market capitalization.
  • While there are no directly related articles, the emphasis on trial data suggests a broader trend in the biotech sector where positive clinical outcomes can substantially influence stock valuations.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it